Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases.
Standard
Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. / Grannas, Gerrit; Neipp, Michael; Hoeper, Marius M; Gottlieb, Jens; Lück, Rainer; Becker, Thomas; Simon, Andre; Strassburg, Christian P; Manns, Michael P; Welte, Tobias; Haverich, Axel; Klempnauer, Jürgen; Nashan, Björn; Strueber, Martin.
in: TRANSPLANTATION, Jahrgang 85, Nr. 4, 4, 2008, S. 524-531.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases.
AU - Grannas, Gerrit
AU - Neipp, Michael
AU - Hoeper, Marius M
AU - Gottlieb, Jens
AU - Lück, Rainer
AU - Becker, Thomas
AU - Simon, Andre
AU - Strassburg, Christian P
AU - Manns, Michael P
AU - Welte, Tobias
AU - Haverich, Axel
AU - Klempnauer, Jürgen
AU - Nashan, Björn
AU - Strueber, Martin
PY - 2008
Y1 - 2008
N2 - BACKGROUND: Combined lung and liver transplantation (Lu-LTx) is a therapeutic option for selected patients with coexisting lung and liver disease. For several reasons, Lu-LTx is performed in few centers and information about the technical issues, posttransplant management and long-term outcomes associated with this procedure is limited. METHODS: We analyzed data from 13 consecutive patients who underwent combined Lu-LTx at Hannover Medical School (Hannover, Germany) between April 1999 and December 2003. The main indications were cystic fibrosis, alpha1-proteinase inhibitor deficiency and portopulmonary hypertension. All patients had advanced cirrhosis and severe pulmonary disease manifestation. RESULTS: Ten patients received a sequential double Lu-LTx, one patient received a single Lu-LTx, one received a double lung and split liver transplantation, and one received an en-bloc heart-lung and liver transplantation. Immunosuppression was based on cyclosporine in a triple/quadruple regimen. Postoperative surgical complications occurred in eight patients. There were two perioperative deaths; two patients died during the first year on day 67 and 354, respectively, and one patient died at month 53. The overall patient survival rates at 1, 3, and 5 years were 69%, 62%, and 49%, respectively. CONCLUSION: Combined Lu-LTx is a therapeutic option for highly selected patients with end-stage lung and liver disease with acceptable long-term outcome.
AB - BACKGROUND: Combined lung and liver transplantation (Lu-LTx) is a therapeutic option for selected patients with coexisting lung and liver disease. For several reasons, Lu-LTx is performed in few centers and information about the technical issues, posttransplant management and long-term outcomes associated with this procedure is limited. METHODS: We analyzed data from 13 consecutive patients who underwent combined Lu-LTx at Hannover Medical School (Hannover, Germany) between April 1999 and December 2003. The main indications were cystic fibrosis, alpha1-proteinase inhibitor deficiency and portopulmonary hypertension. All patients had advanced cirrhosis and severe pulmonary disease manifestation. RESULTS: Ten patients received a sequential double Lu-LTx, one patient received a single Lu-LTx, one received a double lung and split liver transplantation, and one received an en-bloc heart-lung and liver transplantation. Immunosuppression was based on cyclosporine in a triple/quadruple regimen. Postoperative surgical complications occurred in eight patients. There were two perioperative deaths; two patients died during the first year on day 67 and 354, respectively, and one patient died at month 53. The overall patient survival rates at 1, 3, and 5 years were 69%, 62%, and 49%, respectively. CONCLUSION: Combined Lu-LTx is a therapeutic option for highly selected patients with end-stage lung and liver disease with acceptable long-term outcome.
M3 - SCORING: Zeitschriftenaufsatz
VL - 85
SP - 524
EP - 531
JO - TRANSPLANTATION
JF - TRANSPLANTATION
SN - 0041-1337
IS - 4
M1 - 4
ER -